Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC decreased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 63.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,600 shares of the biopharmaceutical company's stock after selling 29,350 shares during the quarter. Commonwealth Equity Services LLC's holdings in Dynavax Technologies were worth $212,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of DVAX. Saturna Capital Corp bought a new position in shares of Dynavax Technologies in the fourth quarter worth about $174,000. Wealthfront Advisers LLC bought a new position in Dynavax Technologies in the 4th quarter worth about $193,000. AlphaQuest LLC increased its position in shares of Dynavax Technologies by 10.2% during the fourth quarter. AlphaQuest LLC now owns 23,437 shares of the biopharmaceutical company's stock worth $299,000 after acquiring an additional 2,172 shares during the period. Amundi increased its position in shares of Dynavax Technologies by 172.6% during the fourth quarter. Amundi now owns 58,896 shares of the biopharmaceutical company's stock worth $743,000 after acquiring an additional 37,290 shares during the period. Finally, E Fund Management Co. Ltd. raised its stake in shares of Dynavax Technologies by 4.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after acquiring an additional 771 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Dynavax Technologies Stock Up 2.6 %

NASDAQ DVAX traded up $0.28 during midday trading on Friday, hitting $11.25. 2,119,183 shares of the company traded hands, compared to its average volume of 2,209,754. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63. The company's 50-day simple moving average is $13.20 and its 200-day simple moving average is $12.58. The company has a market cap of $1.40 billion, a PE ratio of 62.50 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DVAX. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and dropped their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.